Targeting complement factor h for treatment of diseases

C - Chemistry – Metallurgy – 07 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C07K 14/435 (2006.01)

Patent

CA 2656063

The invention provides a CR2-FH molecule comprising a CR2 portion comprising CR2 protein or a fragment thereof and a FH portion comprising a factor H protein or a fragment thereof, and pharmaceutical compositions comprising a CR2-FH molecule. Also provided are methods of using the compositions for treatment diseases in which the alternative complement pathway is implicated, such as age- related macular degeneration, rheumatoid arthritis, and ischemia reperfusion.

La présente invention concerne une molécule de CR2-FH contenant une partie CR2 renfermant une protéine CR2 ou un fragment de celle-ci, et une partie FH renfermant une protéine de facteur H ou un fragment de celle-ci, ainsi que des compositions pharmaceutiques contenant une molécule CR2-FH. L'invention concerne également des procédés d'utilisation des compositions pour le traitement de maladies impliquant la voie alternative du complément, telles qu'une dégénérescence maculaire liée au vieillissement, une polyarthrite rhumatoïde, et une reperfusion ischémique.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Targeting complement factor h for treatment of diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Targeting complement factor h for treatment of diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Targeting complement factor h for treatment of diseases will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1463785

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.